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Human 15-lipoxygenase-1 (15-LOX-1) belongs to the class of lipoxygenases, which catalyze oxygenation of
polyunsaturated fatty acids, such as arachidonic and linoleic acid. Recent studies have shown that 15-LOX-1 plays
an important role in physiological processes linked to several diseases such as airway inflammation disease,
coronary artery disease, and several types of cancer such as rectal, colon, breast and prostate cancer. In this
study, we aimed to extend the structural diversity of 15-LOX-1 inhibitors, starting from the recently identified
indolyl core. In order to find new scaffolds, we employed a combinatorial approach using various aromatic
aldehydes and an aliphatic hydrazide tail. This scaffold-hopping study resulted in the identification of the 3-
pyridylring as a suitable replacement of the indolyl core with an inhibitory activity in the micromolar range
(IC50=16�6 μM) and a rapid and efficient structure–activity relationship investigation.
Keywords: 15-lipoxygenase-1, enzyme inhibitors, combinatorial chemistry, acylhydrazone, structure–activity
relationships.
Introduction
Several diseases on the World Health Organization’s
list of top-ten leading causes of death worldwide in
2016, such as ischemic heart disease, stroke, airway
inflammation disease, and cancer have been associ-
ated with the catalytic action of human 15-lipoxyge-
nase-1 (15-LOX-1).[1–4] This enzyme catalyzes oxygen-
ation of polyunsaturated fatty acids, such as
arachidonic and linoleic acid forming several pro-
inflammatory mediators.[4]
In the arachidonic acid metabolism pathway, 15-
LOX-1 catalyzes the production of hydroperoxy fatty
acid (15S)-hydroperoxyeicosatetraenoic acid ((15S)-
HpETE), which can then be reduced by 5-LOX to
lipoxins, by 15-LOX-1 to eoxins, or by glutathione
peroxidase to (15S)-hydroxyeicosatetraenoic acid
((15S)-HETE).[5] In the linoleic acid metabolism path-
way, 15-LOX-1 transforms the polyunsaturated fatty
acid into (9Z,11E,13S)-13-hydroperoxy-9,11-octadeca-
dienoic acid ((13S)-HpODE), which can then be further
1 These authors contributed equally.
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reduced to (9Z,11E,13S)-13-hydroxy-9,11-octadecadie-
noic acid ((13S)-HODE).[6,7]
(15S)-HETE is reported to be present in the heart
tissue of patients with ischemic heart disease and it
contributes to accelerated clot formation.[8] Also an
increase of 12/15-LOX levels in the peri-infarct cortex
of two stroke patients has been reported, suggesting
their important role in human stroke.[9] Another
metabolite from the linoleic acid metabolism pathway
is (13S)-HODE, which has been shown to induce airway
epithelial injury leading to severe asthma.[10] Further-
more, 15-LOX-1 triggers the formation of several
metabolites, resulting in higher secretion of mucins in
asthmatic patients.[11] These studies suggest the
versatile role of 15-LOX-1 in pathophysiological proc-
esses, which have been linked to various diseases.
Therefore, the discovery of a potent inhibitor of 15-
LOX-1 with physicochemical properties that enable
further drug development is essential to unravel the
biological roles of the enzyme.
Several 15-LOX-1 inhibitors have been reported
featuring moderate to good inhibitory activity, such as
imidazole-based sulfamides,[12] oxadiazole
derivatives,[13] and pyrazole-based sulfamides (Fig-
ure 1).[14] Although these inhibitors exhibit potent
activity against 15-LOX-1, up to now no inhibitor has
reached the market as drug for therapeutic use. This
could be attributed to their unfavorable physicochem-
ical and pharmacokinetic properties, which hampered
their hit-to-lead optimization and call for the discovery
of novel chemical classes.[12,14,15]
In 2015, our group reported a substituted indolyl
moiety with various possible extensions at the 3-
position as a promising core structure for inhibition of
15-LOX-1. The most potent compound, N247, showed
a half maximal inhibitory concentration (IC50) of 0.09�
0.03 μM (Figure 1).[16]
Although the indoles are very potent, their utility is
hindered by their low aqueous solubility. Thus, we
investigated the possibility of scaffold hopping by
starting from the previously reported aliphatic
branched tail as fatty acid mimic.[16] In our search for
new scaffolds, we applied a combinatorial approach
based on acylhydrazone chemistry, in which we let
hydrazide 1d react with various aldehydes. To estab-
lish whether the new scaffold could act as 15-LOX-1
inhibitor, we synthesized a series of acylhydrazones,
2–7. Next, we screened various aromatic aldehydes in
combination with the aliphatic tail as hydrazide (1d),
which resulted in the 3-pyridyl moiety as clear hit.
Encouraged by this discovery, we performed a
combinatorial screening focusing on the 3-pyridyl
moiety that helped us to further explore the chemical
space around the initial hit.
Results and Discussion
Acylhydrazones as Inhibitors of 15-LOX-1
In order to enhance the structural diversity of 15-LOX-
1 inhibitors, we started our study from the recently
identified N247 bearing an indolyl core.[16] Several
studies have shown that even small changes to the
indolyl core, such as methylation of the amine or
modification of the ethyl ester led to a loss of
inhibitory activity.[16,17] In order to investigate whether
the indole replacement would be tolerated in terms of
activity, we used the aliphatic tail of the most potent
indolyl-based inhibitor reported so far as starting point
and performed a preliminary screening assay with six
acylhydrazones 2–7, obtained from reacting the
aliphatic branched tail as hydrazide with various
aldehydes as indole replacement (Scheme 1). Although
the stereochemistry in the aliphatic branched tail can
have an effect on the potency,[16,18] for this preliminary
Figure 1. Structures of representative inhibitors of 15-LOX-1 and initial hit (N247) used as starting point in this study.
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work, we used the racemic mixture. A four-step
synthetic route from commercially available (�)-citro-
nellal afforded hydrazide 1d. Oxidation of citronellal
using Tollens’ reagent, followed by Pd/C-catalyzed
hydrogenation afforded 1b in 96% yield. Next, Fischer
esterification to the methyl ester 1c, followed by
hydrazinolysis provided hydrazide 1d in an overall
yield of 66% over four steps. Subsequently, we
obtained the six acylhydrazones by letting the
hydrazide react with the corresponding aldehydes
(Scheme 1).
In order to mimic the indole, aromatic aldehydes
with 5- and 6-membered rings, displaying various
substitution patterns, were used. We screened the
compounds against 15-LOX-1 by measuring the for-
mation of (13S)-HpODE (λmax of 234 nm) from linoleic
acid using the UV absorption assay as reported
before.[16,18] At 100 μM, compounds 2 and 4 emerged
as the two best compounds with 51% and 66%
inhibition of the enzymatic activity (Figure 2), corre-
sponding to half maximal inhibitory concentrations
(IC50) of 59�7 μM and 42�4 μM, respectively.
Although the IC50 values are much higher than for the
indolyl compounds, scaffold hopping from the indolyl
core to other aromatic moieties is possible.
Screening of Library of Reaction Mixtures
Compounds 2 and 4 show that the indolyl moiety can
be successfully replaced by another aromatic moiety.
Scheme 1. Synthetic route for the preparation of the aliphatic hydrazide 1d and synthesis of initial acylhydrazones 2–7. Reagents
and conditions: a) Ag2O, H2O, r.t., 16 h; b) H2, 10 mol-% Pd/C, EtOH, r.t., 16 h; c) cat. H2SO4, MeOH, reflux, 16 h; d) hydrazine hydrate,
MeOH, reflux, 16 h; e) corresponding aldehyde, MeOH, reflux, 16 h.
Figure 2. Left, residual enzyme activity of 15-LOX-1 after incubation with acylhydrazones 2–7 at 100 μM. Right, IC50 curve of
compound 4. Positive control (PC) shows the enzyme activity in absence of inhibitor. The experiments were performed in triplicate,
and the standard errors are shown.
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To improve the potency of the compounds and find
new scaffolds, we expanded our library with more
aromatic aldehydes. In order to save time and costs,
we employed a combinatorial approach in which we
let hydrazide 1d (1.1 equivalents) react with each of
the 25 aldehydes. We selected various aromatic
aldehydes with diverse substitution patterns and also
included 2–7 (Scheme 2). Under the applied reaction
conditions, the acylhydrazone compounds were
formed with full conversion of the aldehyde starting
material and without the formation of any side
products. Given that 2 and 4 display IC50 values of
around 50 μM we screened each mixture, except for
that with furan aldehyde 5, which was black and
contained insoluble particles, at this concentration. To
account for the 0.1 equivalents of unreacted hydrazide
1d that is expected to be present in the mixtures, we
tested it at 5 μM (Figure 3).
In the screening assay, the previously identified hits
2 and 4 (IC50 59�7 and 42�4 μM, respectively),
resulted in a high residual enzyme activity of around
90%. From the screening of mixtures 17, 21, and 22
emerged as new hits. These compounds lower the
residual enzyme activity to 74%, 47%, and 70%,
respectively. The ortho-hydroxy substituent and the
acylhydrazone motif on 21 and 22 might be able to
coordinate with metals, leading to non-specific inter-
ference with the enzyme inhibition.[19] Since com-
pound 21 showed the highest inhibitory potency of
the screening, we only discarded 22. In order to
confirm the activity of the novel chemical scaffolds, we
synthesized 17 and 21 for determination of their IC50
values. Compound 17, having an IC50 value of 16�
6 μM (Figure 4) can be considered as a novel hit
compound which has a promising activity considering
its structural simplicity. Compound 21 turned out to
be inactive (IC50>100 μM). We suspect that the activity
of compound 21 in the mixture screening might be a
false positive caused by degradation and/or oxidation
of the aldehyde.
Structure–Activity Relationships (SARs) around the
3-Pyridyl Class
Having identified 17 as a hit compound, we focused
the optimization around the aromatic structure of the
3-pyridyl moiety. To do so, we chose a set of eight 3-
pyridyl acylhydrazones bearing various substituents on
the ring, while avoiding ortho-substituents to circum-
vent the possibility of metal chelation. The selection
was based on commercial availability and structural
diversity, including electron-donating substituents,
such as para-hydroxyl (27), para-methyl (34), or meta/
para-methoxy groups (32, 33) and electron-withdraw-
ing groups, such as meta-fluoro (29), meta/para-bromo
(30, 31), and para-trifluoromethyl (28) groups
(Scheme 3).
Scheme 2. Mixtures prepared for the screening assay against 15-LOX-1.
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For the screening of the analogues 27–34, we
included 3-pyridyl 17 as control. Furthermore, to
explore the SAR around the pyridine, we included
compounds 6 (2-pyridyl) and 18 (4-pyridyl) that differ
in the position of the pyridyl ring nitrogen atom.
Interestingly, the SAR was extremely steep and
compounds 6, 18, and 27–34 were all inactive. Even
compound 29, which differs from 17 only in the small
fluorine substituent, does not give a significant
inhibitory activity (Figure 5).
Replication of the screening result demonstrated
that the indolyl moiety can be replaced by other
aromatic functionalities (Figure 3) and that the unsub-
stituted 3-pyridyl moiety is the most potent inhibitor
(Figure 5). Our successful scaffold hopping afforded
the unsubstituted 3-pyridyl as an inhibitor of 15-LOX-1
Figure 3. Residual enzyme activity of 15-LOX-1 after incubation with the mixtures of acylhydrazones 2–26 at 50 μM. Hydrazide 1d
was tested at 5 μM. The positive control (PC) shows the enzyme activity in absence of inhibitor. The experiment was performed in
triplicate, and the standard error is shown.
Figure 4. The IC50 curve of compound 17. Measurement was
performed two times in triplicate.
Scheme 3. Synthesis of acylhydrazones 27–34 for optimization based on the 3-pyridyl moiety.
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with an IC50 value of 16�6 μM. The addition of
strongly or weakly electron-donating or -withdrawing
groups does not influence the activity. Presumably,
this compound occupies a very narrow and specific
binding pocket, which does not tolerate the presence
of additional substituents, not even a small fluorine
atom.
Replacement of the Aliphatic Branched Tail
Having identified the 3-pyridyl moiety as the best
replacement of the indolyl moiety, we turned our
attention to the aliphatic tail. We recently discovered
that the aliphatic tail in 3-position of the substituted
indole could be replaced by different moieties, without
a large loss in activity.[20] Therefore, we investigated
the possibility of combining the 3-pyridyl moiety with
hydrazides bearing the four most potent side-groups
from our previous study. The four different aromatic
hydrazides consisted of an ortho-chloro phenoxy (35),
an ortho,para-dichloro phenoxy (36), a benzimidazolyl
(37), and a meta,para-dimethoxy benzyl (38) moiety
(Scheme 4). Compared to the aliphatic branched tail,
the calculated logP (cLogP) of the different structures
and substituents is lowered significantly (Table S1). For
future applications and optimizations, these could be
interesting starting points compared to the highly
lipophilic tail. Unfortunately, biochemical evaluation of
the four synthesized acylhydrazones at 50 μM showed
no improvement in inhibitory activity compared to
compound 17 (Figure 6).
Conclusions
In this study, we report on a successful example of
scaffold hopping, in which we replaced the established
indolyl moiety by other aromatic moieties. Screening
Figure 5. Residual enzyme activity of 15-LOX-1 after incubation with purified 2-, 3-, and 4-pyridyl acylhydrazones (6, 17, and 18)
and substituted 3-pyridyl derivatives (27–34) at 50 μM. Positive control (PC) shows the enzyme activity in absence of inhibitor. The
experiment was performed in triplicate and the standard error is shown.
Scheme 4. Synthesis of acylhydrazones 35–38 with selected
hydrazides using 3-pyridine carboxaldehyde.
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of mixtures with a library containing 24 various
commercially available aldehydes and an aliphatic
hydrazide resulted in 3-pyridine 17 as the most potent
inhibitor (IC50=16�6 μM) despite its structural sim-
plicity. Attempts in further optimizing the 3-pyridyl
scaffold using several electron-donating and -with-
drawing substituents surprisingly resulted in loss of
potency. Of the compounds used in this study, the
unsubstituted 3-pyridyl acylhydrazone is the optimal
replacement for the indolyl moiety, which constitutes
a starting point for future optimization.
Experimental Section
Enzyme Inhibition Studies
The human 15-LOX-1 enzyme was expressed and
purified as described before.[18] The activity of 15-LOX-
1 was measured by the conversion of linoleic acid into
(9Z,11E,13S)-13-hydroperoxy-9,11-octadecadienoic
acid ((13S)-HpODE) (λmax 234 nm) using a Synergy H1
hybrid plate reader.[16,18] The conversion rate was
followed by measuring the increase in UV absorption
over time. The linear part of the plot of the conversion
rate was assessed, typically between one and ten
minutes.
Screening Assay
The assay was performed using a 96-well plate and
HEPES buffer (25 mM, pH 7.5). The substrate, linoleic
acid (LA) (Sigma-Aldrich, L1376), was diluted in ethanol
to 500 μM. The inhibitor (10 mM in DMSO) was diluted
in assay buffer to a concentration of 71.4 μM. The
inhibitor solution of 140 μL was mixed with 50 μL of
enzyme solution and incubated for 8 min at room
temperature. After which, 10 μL of linoleic acid
solution was added, which resulted in a mixture with a
final dilution of the enzyme of 1 : 640, 25 μM of the
substrate, and 50 μM of the inhibitors (100 μM in
preliminary screening). The linear increase of absorb-
ance in the absence of the inhibitor was set to 100%,
whereas the increase of absorbance in the absence of
the enzyme was set to 0%. All experiments were
performed in triplicate, the averages and standard
errors were calculated.
IC50 Determination
The half-maximal inhibitory concentration (IC50) of the
h-15-LOX-1 inhibitors was determined using the
procedures as shown above. Using a serial dilution,
the desired final concentrations of the inhibitors were
achieved ranging from 200 to 0.39 μM. Data analysis
was performed using Microsoft Excel professional plus
2016 and GraphPad Prism 5.00.
Chemistry
General Methods. All reagents were purchased from
Sigma–Aldrich, TCI Europe, Fluorochem, or Acros Organ-
ics without purification, unless otherwise stated. All
solvents were reagent-grade. Reactions were moni-
tored with thin layer chromatography (TLC) on silica
gel-coated aluminum (silica gel 60/Kieselguhr 254,
Merck). Purification was performed using flash column
chromatography on silica gel (SiliCycle 40–63 μm,
230–400 mesh) or using automated column chroma-
tography (Reveleris® flash purification system from
Grace Discovery Sciences). Melting points were meas-
ured on a Stuart® SMP11 50 W melting point appara-
tus. NMR spectra were recorded on a Varian AMX400
or Bruker Ascend™ 600 MHz spectrometer at 25 °C.
Chemical shifts (δ) are reported in ppm relative to the
residual solvent peak for 1H-NMR and 13C-NMR or
relative to trifluoroacetic acid (TFA, in insert) for 19F-
NMR. Splitting patterns are indicated as (s) singlet, (d)
doublet, (t) triplet, (q) quartet, (quint.) quintet, (m)
multiplet, and (br.) broad. Coupling constants (J) are
reported in Hertz (Hz). High-resolution mass spectra
were recorded using a Thermo Scientific LTQ Orbitrap-
XL mass spectrometer (mass accuracy <4 ppm). Com-
pounds 1a and 1b were synthesized according to
literature procedures and all data were in agreement
with those previously reported.[16] All final compounds
Figure 6. Residual enzyme activity of 15-LOX-1 after incubation
with 50 μM of 3-pyridyl derivatives 35–38. Positive control (PC)
shows the enzyme activity in absence of inhibitor. The experi-
ment was performed in triplicate and the standard error is
shown.
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were analyzed by UPLC-MS (Thermo Fischer Scientific
Vanquish with LCQ Fleet detector, 254 nm) confirming
purity �95% (see Supporting Information).
Procedure for the Preparation of Mixtures. The
aldehydes (0.2 mmol) were weighed into 4 mL vials.
DMSO (500 μL) was added to reach a concentration of
0.4 mM. The hydrazide (3.3 mmol) was weighed in a
20 mL vial, after which it was dissolved in DMSO
(7.5 mL), resulting in a concentration of 0.44 mM. Then,
to 1 mL Eppendorf tubes, was added the correspond-
ing aldehyde (250 μL) and hydrazide 1d (250 μL),
resulting in a final concentration of 0.2 mM aldehyde
and 1.1 equiv. of hydrazide. All reaction mixtures were
mixed, shortly centrifuged, and then placed in an
aluminum heating block pre-heated to 90 °C over-
night.
General procedure for the synthesis of acylhydrazones
(GP-A). To a solution of hydrazide 1d (1.0 equiv.) in
MeOH (ca. 0.07 M), the corresponding aldehyde (1.2–
1.3 equiv.) was added, and the mixture was stirred at
reflux overnight (16–18 h). Then, the mixture was
concentrated under reduced pressure, and the crude
was purified by flash column chromatography. The
corresponding acylhydrazones were obtained as mix-
tures of Esyn and Eanti isomers (approximately 1 : 1
ratio)[21] in 55–98% yield, and the peaks of both
isomers are reported in the 1H- and 13C-NMR spectra.
methyl (�)-3,7-Dimethyloctanoate (1c). Acid 1b
(893 mg, 5.18 mmol) was dissolved in MeOH (50 mL,
0.10 M), after which a few drops of sulfuric acid were
added, and the mixture was heated to reflux over-
night. Then, the mixture was allowed to cool down to
room temperature, and the solvent was evaporated
under reduced pressure. The resulting crude was
dissolved in diethyl ether. The organic layer was
washed with a saturated aq. solution of NaHCO3 and a
saturated aq. solution of NaCl. The organic layer was
dried over MgSO4, filtered, and evaporated to dryness
under reduced pressure to afford the product as
colorless oil (898 mg, 4.82 mmol, 93% yield). 1H-NMR
(400 MHz, CDCl3): 3.66 (s, 3 H); 2.30 (dd, J=14.7, 6.0, 1
H); 2.11 (dd, J=14.7, 8.1, 1 H); 2.02–1.84 (m, 1 H);
1.58–1.44 (m, 1 H); 1.37–1.08 (m, 6 H); 0.92 (d, J=6.6,
3 H); 0.85 (d, J=6.6, 6 H). 13C-NMR (101 MHz, CDCl3):
174.0 (C); 51.5 (CH3); 41.8 (CH2); 39.2 (CH2); 37.1 (CH2);
30.5 (CH); 28.1 (CH); 24.8 (CH2); 22.8 (CH3); 22.7 (CH3);
19.9 (CH3). HR-MS: 1c could not be ionized in ESI+
and APCI experiments.
(�)-3,7-Dimethyloctanehydrazide (1d). To a sol-
ution of the methyl ester 1c (1.34 g, 7.19 mmol) in
MeOH (71 mL, 0.10 M), hydrazine hydrate (55%, 4.5 mL,
51 mmol, 7 equiv.) was added. The mixture was heated
to reflux overnight and then allowed to cool down to
room temperature, and the solvent was evaporated
under reduced pressure. The crude was purified by
flash column chromatography, eluting with CH2Cl2/
MeOH (97 :3). Hydrazide 1d was obtained as white
solid (1.07 g, 5.74 mmol, 80% yield). M.p. 68–70 °C. 1H-
NMR (400 MHz, (D6)DMSO): 8.89 (s, 1 H); 4.13 (s, 2 H);
2.05–1.91 (m, 1 H); 1.86–1.74 (m, 2 H); 1.58–1.43 (m, 1
H); 1.32–0.98 (m, 6 H); 0.90–0.75 (m, 9 H). 13C-NMR
(101 MHz, (D6)DMSO): 171.0 (C); 41.1 (CH2); 38.6 (CH2);
36.4 (CH2); 29.9 (CH); 27.3 (CH); 24.1 (CH2); 22.6 (CH3);
22.4 (CH3); 19.4 (CH3). HR-ESI-MS (pos.): 187.1813
(C10H23N2O
+, [M+H]+; calc. 187.1805).
3,7-Dimethyl-N’-(thiophen-2-ylmethylene)
octanehydrazide (2). This compound was synthesized
according to GP-A, starting with thiophene-2-carbalde-
hyde (42 mg, 0.37 mmol, 1.3 equiv.). The crude was
purified by flash column chromatography (CH2Cl2/
MeOH 99:1) to afford the product as yellow oil (67 mg,
0.24 mmol, 87%). 1H-NMR (400 MHz, (D6)DMSO): 11.25
(s, 1 H); 11.17 (s, 1 H); 8.39 (s, 1 H); 8.13 (s, 1 H); 7.62 (d,
J=5.0, 1 H); 7.58 (d, J=5.0, 1 H); 7.42–7.39 (m, 1 H);
7.38–7.33 (m, 1 H); 7.18–7.04 (m, 2 H); 2.57 (dd, J=
13.9, 5.7, 1 H); 2.31 (dd, J=13.8, 8.2, 1 H); 2.15 (dd, J=
13.6, 5.8, 1 H); 2.03–1.83 (m, 3 H); 1.58–1.44 (m, 2 H);
1.36–1.05 (m, 12 H); 0.94–0.86 (m, 6 H); 0.86–0.82 (m,
12 H). 13C-NMR (101 MHz, (D6)DMSO): 173.6 (C); 168.0
(C); 141.0 (CH); 139.21 (C); 139.19 (C); 137.4 (CH); 130.5
(CH); 129.8 (CH); 128.6 (CH); 127.9 (CH); 127.8 (CH);
127.7 (CH); 41.9 (CH2); 39.2 (CH2); 38.6 (2 CH2), 36.7
(CH2); 36.4 (CH2); 30.0 (CH); 29.6 (CH); 27.3 (2 CH);
24.11 (CH2); 24.07 (CH2); 22.6 (CH3); 22.5 (CH3); 22.45
(CH3); 22.43 (CH3); 19.8 (CH3); 19.5 (CH3). HR-ESI-MS
(pos.): 281.168 (C15H25N2OS
+, [M+H]+; calc. 281.168).
N’-[(1H-Imidazol-4-yl)methylene]-3,7-dimethyl-
octanehydrazide (3). This compound was synthesized
according to GP-A, starting with 1H-imidazole-4-carbal-
dehyde (35 mg, 0.37 mmol, 1.3 equiv.). The crude was
purified by flash column chromatography (CH2Cl2/
MeOH 95:5) to afford the product as white solid
(47 mg, 0.18 mmol, 64%). M.p. 151–154 °C. 1H-NMR
(600 MHz, (D6)DMSO): 12.76–12.26 (m, 2 H); 11.22–
10.88 (m, 2 H); 8.19–8.05 (m, 1 H); 7.90 (s, 1 H); 7.78–
7.67 (m, 2 H); 7.56–7.44 (m, 1 H); 7.32–7.21 (m, 1 H);
2.57–2.34 (m, 2 H, overlap with DMSO), 2.24–2.08 (m,
1 H); 2.01–1.85 (m, 3 H); 1.57–1.44 (m, 2 H); 1.35–1.19
Helv. Chim. Acta 2019, 102, e1900040
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(m, 6 H); 1.18–1.06 (m, 6 H); 0.90–0.88 (m, 6 H); 0.86–
0.83 (m, 12 H). 13C-NMR (151 MHz, (D6)DMSO): 173.3
(C); 167.5 (C); 142.0 (CH); 138.7 (2 CH); 136.58 (C);
136.56 (C); 136.4 (2 CH); 132.8 (CH); 132.3 (CH); 131.2
(CH); 116.5 (CH); 113.3 (CH); 41.9 (CH2); 38.6 (2 CH2),
36.6 (CH2); 36.4 (CH2); 30.0 (CH); 29.3 (CH); 27.36 (CH);
27.34 (CH); 24.2 (CH2); 24.1 (CH2); 22.6 (CH3); 22.5 (CH3);
22.4 (2 CH3), 19.8 (CH3); 19.5 (CH3). Note: one of the
CH2 signals, α to the carbonyl, is overlapping with the
DMSO signal. Multiple isomers of the imidazole moiety
are observed in the carbon NMR spectrum (see gHSQC
in Supporting Information). HR-ESI-MS (pos.): 265.203
(C14H25N4O
+, [M+H]+; calc. 265.202).
N’-[(4-Hydroxy-3-methoxyphenyl)methylidene]-
3,7-dimethyloctanehydrazide (4). This compound
was synthesized according to GP-A, starting with 4-
hydroxy-3-methoxybenzaldehyde (53 mg, 0.35 mmol,
1.2 equiv.). The crude was purified by flash column
chromatography (CH2Cl2/MeOH 99:1) to afford the
product as white solid (71 mg, 0.22 mmol, 79%). M.p.
126–129 °C. 1H-NMR (400 MHz, (D6)DMSO): 11.11 (s, 1
H); 11.02 (s, 1 H); 9.45 (br. s, 2 H); 8.03 (s, 1 H); 7.84 (s, 1
H); 7.25 (s, 1 H); 7.19 (s, 1 H); 7.07–6.97 (m, 2 H); 6.80
(2dd overlap, J=8.1, 1.5, 2 H); 3.81 (d, J=1.6, 3 H); 3.79
(d, J=1.6, 3 H); 2.66–2.75 (m, 1 H); 2.40–2.31 (m, 1 H);
2.18–2.10 (m, 1 H); 2.03–1.86 (m, 3 H); 1.60–1.41 (m, 2
H); 1.36–1.21 (m, 6 H); 1.20–1.07 (m, 6 H); 0.92–0.86
(m, 6 H); 0.87–0.81 (m, 12 H). 13C-NMR (101 MHz, (D6)
DMSO): 173.6 (C); 167.7 (C); 148.8 (C); 148.5 (C); 148.0
(C); 147.9 (C); 146.3 (CH); 142.6 (CH); 125.83 (C); 125.75
(C); 121.9 (CH); 120.7 (CH); 115.6 (CH); 115.4 (CH); 109.5
(CH); 108.9 (CH); 55.52 (CH3); 55.45 (CH3); 41.9 (CH2);
39.47 (CH2); 38.6 (2 CH2), 36.7 (CH2); 36.4 (CH2); 30.1
(CH); 29.6 (CH); 27.34 (CH); 27.32 (CH); 24.13 (CH2);
24.08 (CH2); 22.6 (CH3); 22.5 (CH3); 22.4 (2 CH3), 19.8
(CH3); 19.5 (CH3). HR-ESI-MS (pos.): 321.218
(C18H29N2O3
+, [M+H]+; calc. 321.217).
N’-[(Furan-2-yl)methylidene]-3,7-dimethyl-
octanehydrazide (5). This compound was synthesized
according to GP-A, starting with furan-2-carbaldehyde
(32 mg, 0.33 mmol, 1.2 equiv.). The crude was purified
by flash column chromatography (CH2Cl2/MeOH 99:1)
to afford the product as brown oil (70 mg, 0.26 mmol,
95%). 1H-NMR (400 MHz, (D6)DMSO): 11.24 (s, 1 H);
11.14 (s, 1 H); 8.06 (s, 1 H); 7.85 (s, 1 H); 7.82–7.74 (m, 2
H); 6.90–6.76 (m, 2 H); 6.61–6.58 (m, 2 H); 2.57 (dd, J=
13.9, 5.7, 1 H); 2.37 (dd, J=14.9, 8.2, 1 H); 2.16 (dd, J=
13.6, 5.8, 1 H); 2.05–1.79 (m, 3 H); 1.58–1.44 (m, 2 H);
1.36–1.05 (m, 12 H); 0.91–0.86 (m, 6 H); 0.86–0.82 (m,
12 H). 13C-NMR (101 MHz, (D6)DMSO): 173.7 (C); 168.0
(C); 149.5 (C); 149.4 (C); 144.9 (CH); 144.7 (CH); 135.7
(CH); 132.5 (CH); 113.0 (CH); 112.7 (CH); 112.1 (CH);
112.0 (CH); 41.9 (CH2); 38.9 (CH2); 38.60 (CH2); 38.58
(CH2); 36.6 (CH2); 36.4 (CH2); 30.0 (CH); 29.2 (CH); 27.4
(2 CH); 24.10 (CH2); 24.06 (CH2); 22.6 (CH3); 22.5 (CH3);
22.4 (2 CH3), 19.8 (CH3); 19.5 (CH3). HR-ESI-MS (pos.):
265.191 (C15H25N2O2
+, [M+H]+; calc. 265.191).
3,7-Dimethyl-N’-[(pyridin-2-yl)methylidene]octa-
nehydrazide (6). This compound was synthesized
according to GP-A, starting with picolinaldehyde
(41 mg, 0.38 mmol, 1.4 equiv.). The crude was purified
by flash column chromatography (CH2Cl2/MeOH 99:1)
to afford the product as yellow oil (75 mg, 0.27 mmol,
98%). 1H-NMR (400 MHz, (D6)DMSO): 11.53 (s, 1 H);
11.42 (s, 1 H); 8.61–8.48 (m, 2 H); 8.18 (s, 1 H); 8.01 (s, 1
H); 8.61–7.48 (m, 4 H); 7.44–7.25 (m, 2 H); 2.65 (dd, J=
14.4, 5.7, 1 H); 2.43 (dd, J=14.3, 8.1, 1 H); 2.21 (dd, J=
13.9, 6.0, 1 H); 2.09–1.86 (m, 3 H); 1.57–1.43 (m, 2 H);
1.36–1.04 (m, 12 H); 0.95–0.87 (m, 6 H); 0.87–0.78 (m,
12 H). 13C-NMR (101 MHz, (D6)DMSO): 174.1 (C); 168.4
(C); 153.3 (C); 153.2 (C); 149.5 (2 CH); 146.0 (CH); 142.8
(CH); 136.8 (CH); 136.7 (CH); 124.2 (CH); 124.0 (CH);
119.7 (CH); 119.2 (CH); 41.9 (CH2); 39.13 (CH2); 38.60
(CH2); 38.58 (CH2); 36.6 (CH2); 36.4 (CH2); 30.0 (CH); 29.5
(CH); 27.4 (2 CH); 24.2 (CH2); 24.1 (CH2); 22.6 (CH3); 22.5
(CH3); 22.4 (2 CH3), 19.8 (CH3); 19.5 (CH3). HR-ESI-MS
(pos.): 276.207 (C16H26N3O
+, [M+H]+; calc. 276.207).
N’-[(2-Methoxyphenyl)methylidene]-3,7-dimeth-
yloctanehydrazide (7). This compound was synthe-
sized according to GP-A, starting with 2-methoxyben-
zaldehyde (48 mg, 0.35 mmol, 1.3 equiv.). The crude
was purified by flash column chromatography (CH2Cl2/
MeOH 99.5:0.5) to afford the product as white solid
(79 mg, 0.26 mmol, 94%). M.p. 88–90 °C. 1H-NMR
(400 MHz, (D6)DMSO): 11.30 (s, 1 H); 11.17 (s, 1 H); 8.51
(s, 1 H); 8.30 (s, 1 H); 7.77 (t, J=8.4, 2 H); 7.42–7.30 (m,
2 H); 7.12–7.04 (m, 2 H); 6.98 (q, J=7.5, 2 H); 3.85–3.81
(m, 6 H); 2.64 (dd, J=14.2, 5.8, 1 H); 2.37 (dd, J=14.1,
8.1, 1 H); 2.16 (dd, J=13.5, 5.7, 1 H); 2.05–1.82 (m, 3 H);
1.57–1.42 (m, 2 H); 1.34–1.05 (m, 12 H); 0.92–0.86 (m,
6 H); 0.86–0.81 (m, 12 H). 13C-NMR (101 MHz, (D6)
DMSO): 173.8 (C); 167.9 (C); 157.6 (C); 157.5 (C); 141.1
(CH); 137.9 (CH); 131.3 (CH); 131.0 (CH); 125.4 (CH);
125.0 (CH); 122.4 (C); 122.3 (C); 120.7 (CH); 120.6 (CH);
111.78 (CH); 111.76 (CH); 55.7 (CH3); 55.63 (CH3); 41.9
(CH2); 39.33 (CH2); 38.61 (CH2); 38.59 (CH2); 36.7 (CH2);
36.5 (CH2); 30.1 (CH); 29.5 (CH); 27.36 (CH); 27.35 (CH);
24.2 (CH2); 24.1 (CH2); 22.6 (CH3); 22.5 (CH3); 22.4 (2
CH3), 19.9 (CH3); 19.5 (CH3). HR-ESI-MS (pos.): 305.222
(C18H29N2O2
+, [M+H]+; calc. 305.222).
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3,7-Dimethyl-N’-[(pyridin-3-yl)methylidene]octa-
nehydrazide (17). This compound was synthesized
according to GP-A, starting with nicotinaldehyde
(35 mg, 0.32 mmol, 1.2 equiv.). The crude was purified
by flash column chromatography (CH2Cl2/MeOH 97 :3)
to afford the product as pale yellow solid (72 mg,
0.26 mmol, 97%). M.p. 76–77 °C. 1H-NMR (400 MHz,
(D6)DMSO): 11.47 (s, 1 H); 11.37 (s, 1 H); 8.80 (s, 2 H);
8.57 (s, 2 H); 8.21 (s, 1 H); 8.10–8.01 (m, 2 H); 8.00 (s, 1
H); 7.49–7.40 (m, 2 H); 2.64 (dd, J=14.3, 5.7, 1 H); 2.42
(dd, J=14.3, 8.1, 1 H); 2.20 (dd, J=13.9, 6.0, 1 H); 2.07–
1.87 (m, 3 H); 1.58–1.43 (m, 2 H); 1.39–1.05 (m, 12 H);
0.93–0.88 (m, 6 H); 0.84 (t, J=7.0, 12 H). 13C-NMR
(101 MHz, (D6)DMSO): 174.1 (C); 168.3 (C); 150.5 (CH);
150.2 (CH); 148.6 (CH); 148.2 (CH); 143.0 (CH); 139.5
(CH); 133.3 (CH); 133.1 (CH); 130.29 (C); 130.25 (C);
123.9 (2 CH); 41.9 (CH2); 39.2 (CH2); 38.59 (CH2); 38.58
(CH2); 36.6 (CH2); 36.4 (CH2); 30.0 (CH); 29.5 (CH); 27.3
(2 CH); 24.12 (CH2); 24.07 (CH2); 22.6 (CH3); 22.5 (CH3);
22.4 (2 CH3), 19.8 (CH3); 19.5 (CH3). HR-ESI-MS (pos.):
276.207 (C16H26N3O
+, [M+H]+; calc. 276.207).
3,7-Dimethyl-N’-[(pyridin-4-yl)methylidene]octa-
nehydrazide (18). This compound was synthesized
according to GP-A, starting with isonicotinaldehyde
(78 mg, 0.73 mmol, 1.7 equiv.). The crude was purified
by flash column chromatography (CH2Cl2/MeOH
97.5 :2.5) to afford the product as yellow oil (90 mg,
0.33 mmol, 78%). 1H-NMR (400 MHz, (D6)DMSO): 11.58
(s, 1 H); 11.49 (s, 1 H); 8.69–8.55 (m, 4 H); 8.17 (s, 1 H);
7.95 (s, 1 H); 7.66–7.56 (m, 4 H); 2.66 (dd, J=14.3, 5.9,
1 H); 2.44 (dd, J=14.3, 8.1, 1 H); 2.22 (dd, J=14.1, 6.1, 1
H); 2.14–1.86 (m, 3 H); 1.58–1.43 (m, 2 H); 1.37–1.05
(m, 12 H); 0.94–0.88 (m, 6 H); 0.87–0.81 (m, 12 H). 13C-
NMR (101 MHz, (D6)DMSO) 174.3 (C); 168.5 (C); 150.2 (4
CH); 143.3 (CH); 141.6 (C); 141.5 (C); 139.8 (CH); 130.6
(CH); 121.2 (CH); 120.9 (CH); 120.6 (CH); 41.9 (CH2);
39.16 (CH2); 38.58 (2 CH2), 36.6 (CH2); 36.4 (CH2); 30.0
(CH); 29.5 (CH); 27.3 (2 CH); 24.13 (CH2); 24.05 (CH2);
22.54 (CH3); 22.51 (CH3); 22.4 (2 CH3), 19.8 (CH3); 19.5




dimethyloctanehydrazide (21). This compound was
synthesized according to GP-A, starting with 2,3-
dihydroxybenzaldehyde (45 mg, 0.32 mmol,
1.2 equiv.). The crude was purified by flash column
chromatography (CH2Cl2/MeOH 99 :1) to afford the
product as brown solid (71 mg, 0.23 mmol, 86%). M.p.
148–151 °C. 1H-NMR (400 MHz, (D6)DMSO): 8.30 (s, 1
H); 8.24 (s, 1 H); 7.04 (d, J=7.8, 1 H); 6.91 (d, J=7.7, 1
H); 6.86–6.77 (m, 2 H); 6.75–6.63 (m, 2 H); 2.57 (dd, J=
14.2, 6.0, 1 H); 2.35 (dd, J=14.4, 7.8, 1 H); 2.21 (dd, J=
13.7, 5.9, 1 H); 2.10–1.85 (m, 3 H); 1.62–1.43 (m, 2 H);
1.37–1.07 (m, 12 H); 0.93–0.88 (m, 6 H); 0.86–0.82 (m,
12 H). Note: none of the exchangeable protons were
observed. 13C-NMR (101 MHz, (D6)DMSO): 173.3 (C);
167.8 (C); 147.1 (CH); 145.9 (C); 145.6 (C); 145.5 (C);
145.1 (C); 141.5 (CH); 120.4 (C); 119.9 (CH); 119.2 (CH);
119.0 (CH); 118.7 (C); 117.22 (CH); 117.16 (CH); 116.5
(CH); 41.6 (CH2); 39.39 (CH2); 38.58 (2 CH2), 36.6 (CH2);
36.4 (CH2); 30.0 (CH); 29.4 (CH); 27.3 (2 CH); 24.12
(CH2); 24.06 (CH2); 22.55 (CH3); 22.53 (CH3); 22.4 (2
CH3), 19.8 (CH3); 19.5 (CH3). HR-ESI-MS (pos.): 307.202
(C17H27N2O3
+, [M+H]+; calc. 307.202).
N’-[(6-Hydroxypyridin-3-yl)methylidene]-3,7-
dimethyloctanehydrazide (27). This compound was
synthesized according to GP-A, starting with 6-hydrox-
ynicotinaldehyde (63 mg, 0.51 mmol, 1.2 equiv.). The
crude was purified by flash column chromatography
(CH2Cl2/MeOH 92 :8) to afford the product as white
solid (110 mg, 0.38 mmol, 90%). M.p. 148–151 °C. 1H-
NMR (400 MHz, (D6)DMSO): 11.85 (s, 2 H); 11.15 (s, 1 H);
11.06 (s, 1 H); 7.96 (s, 1 H); 7.82 (t, J=2.8, 1 H); 7.80 (t,
J=2.8, 1 H); 7.75 (s, 1 H); 7.69 (d, J=2.5, 1 H); 7.64 (d,
J=2.5, 1 H); 6.41 (d, J=2.5, 1 H); 6.38 (d, J=2.5, 1 H);
2.57 (dd, J=14.3, 6.0, 1 H); 2.35 (dd, J=14.2, 8.0, 1 H);
2.13 (dd, J=13.5, 5.8, 1 H); 2.01–1.82 (m, 3 H); 1.59–
1.41 (m, 2 H); 1.34–1.04 (m, 12 H); 0.95–0.78 (m, 18 H).
13C-NMR (101 MHz, (D6)DMSO): 173.5 (C); 167.7 (C);
162.3 (C); 162.2 (C); 142.7 (CH); 139.1 (CH); 137.3 (CH);
136.8 (CH); 136.6 (CH); 136.4 (CH); 120.8 (CH); 120.7
(CH); 113.5 (2 C), 41.8 (CH2); 39.19 (CH2); 38.62 (CH2);
38.60 (CH2); 36.6 (CH2); 36.4 (CH2); 30.1 (CH); 29.4 (CH);
27.4 (2 CH); 24.2 (CH2); 24.1 (CH2); 22.6 (CH3); 22.5
(CH3); 22.4 (2 CH3), 19.9 (CH3); 19.5 (CH3). HR-ESI-MS
(pos.): 292.202 (C16H26N3O2
+, [M+H]+; calc. 292.202).
3,7-Dimethyl-N’-{[6-(trifluoromethyl)pyridin-3-
yl]methylidene}octanehydrazide (28). This com-
pound was synthesized according to GP-A, staring
with 6-(trifluoromethyl)nicotinaldehyde (88 mg,
0.50 mmol, 1.2 equiv.). The crude was purified by flash
column chromatography (CH2Cl2/MeOH 94 :6) to af-
ford the product as pale yellow solid (137 mg,
0.398 mmol, 96%). M.p. 109–111 °C. 1H-NMR
(600 MHz, (D6)DMSO): 11.66 (s, 1 H); 11.58 (s, 1 H); 8.99
(s, 2 H); 8.34 (d, J=8.2, 1 H); 8.32–8.28 (m, 2 H); 8.08 (s,
1 H); 7.96 (d, J=8.2, 1 H); 7.94 (d, J=8.2, 1 H); 2.66 (dd,
J=14.4, 6.0, 1 H); 2.46 (dd, J=14.5, 8.0, 1 H); 2.23 (dd,
J=14.1, 6.1, 1 H); 2.05 (dd, J=14.0, 8.1, 1 H); 2.00–1.87
(m, 2 H); 1.55–1.44 (m, 2 H); 1.37–1.07 (m, 12 H); 0.92
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(d, J=6.6, 3 H); 0.90 (d, J=6.6, 3 H); 0.86–0.80 (m, 12
H). 13C-NMR (151 MHz, (D6)DMSO): 174.3 (C); 168.5 (C);
148.7 (CH); 148.4 (CH); 146.3 (dq overlap, J=34.2, 2
CCF3), 141.5 (CH); 138.0 (CH); 135.5 (CH); 135.1 (CH);
133.7 (C); 133.6 (C); 121.58 (q overlap, J=273.8, 2 CF3),
120.90 (2 CH); 41.9 (CH2); 39.15 (CH2); 38.60 (CH2);
38.57 (CH2); 36.6 (CH2); 36.4 (CH2); 30.0 (CH); 29.5 (CH);
27.3 (2 CH); 24.11 (CH2); 24.07 (CH2); 22.6 (CH3); 22.5
(CH3); 22.4 (2 CH3), 19.8 (CH3); 19.5 (CH3).
19F-NMR
(376 MHz, (D6)DMSO):   67.96 (d, J=8.1). HR-ESI-MS
(pos.): 344.195 (C17H25F3N3O
+, [M+H]+; calc. 344.194).
N’-[(5-Fluoropyridin-3-yl)methylidene]-3,7-di-
methyloctanehydrazide (29). This compound was
synthesized according to GP-A, starting with 5-fluoro-
nicotinaldehyde (67 mg, 0.53 mmol, 1.2 equiv.). The
crude was purified by flash column chromatography
(CH2Cl2/MeOH 98:2) to afford the product as white
solid (125 mg, 0.426 mmol, 98%). M.p. 60–62 °C. 1H-
NMR (400 MHz, (D6)DMSO): 11.53 (2s overlap, 2 H);
8.71 (s, 1 H); 8.69 (s, 1 H); 8.62–8.53 (m, 2 H); 8.26 (s, 1
H); 8.02 (s, 1 H); 7.93 (dd, J=9.9, 2.6, 2 H); 2.68 (dd, J=
14.3, 5.8, 1 H); 2.41 (dd, J=14.3, 8.2, 1 H); 2.21 (dd, J=
14.0, 6.1, 1 H); 2.10–1.84 (m, 3 H); 1.62–1.42 (m, 2 H);
1.36–1.04 (m, 12 H); 0.90 (t, J=7.2, 6 H); 0.86–0.80 (m,
12 H). 13C-NMR (101 MHz, (D6)DMSO): 174.2 (C); 168.4
(C); 159.19 (d, J=254.5, C), 159.14 (d, J=254.5, C),
144.7 (d, J=3.6, CH); 144.5 (d, J=3.6, CH); 141.70 (CH);
141.67 (CH); 138.82–137.95 (m, 2 CH); 132.3 (C); 132.2
(C); 119.6 (d, J=19.2, CH); 119.3 (d, J=19.2, CH); 41.9
(CH2); 39.16 (CH2); 38.59 (2 CH2), 36.6 (CH2); 36.4 (CH2);
30.0 (CH); 29.6 (CH); 27.3 (2 CH); 24.2 (CH2); 24.1 (CH2);
22.6 (CH3); 22.5 (CH3); 22.4 (2 CH3), 19.8 (CH3); 19.5
(CH3).
19F-NMR (376 MHz, (D6)DMSO):   128.51 (d, J=
9.7),   128.56 (d, J=9.8). HR-ESI-MS (pos.): 294.198
(C16H25FN3O
+, [M+H]+; calc. 294.198).
N’-[(6-Bromopyridin-3-yl)methylidene]-3,7-di-
methyloctanehydrazide (30). This compound was
synthesized according to GP-A, starting with 6-bromo-
nicotinaldehyde (68 mg, 0.37 mmol, 1.3 equiv.). The
crude was purified by flash column chromatography
(CH2Cl2/MeOH 97.5 :2.5) to afford the product as white
solid (54 mg, 0.15 mmol, 55%). M.p. 113–115 °C. 1H-
NMR (400 MHz, (D6)DMSO): 11.54 (s, 1 H); 11.45 (s, 1 H);
8.60 (dt, J=7.9, 2.1, 2 H); 8.19 (s, 1 H); 8.07–7.98 (m, 2
H); 7.97 (s, 1 H); 7.74–7.60 (m, 2 H); 2.63 (dd, J=14.3,
5.8, 1 H); 2.43 (dd, J=14.3, 8.2, 1 H); 2.20 (dd, J=14.0,
6.1, 1 H); 2.05–1.81 (m, 3 H); 1.63–1.41 (m, 2 H); 1.38–
1.06 (m, 12 H); 0.93–0.87 (m, 6 H); 0.86–0.81 (m, 12 H).
13C-NMR (101 MHz, (D6)DMSO): 174.1 (C); 168.4 (C);
149.2 (CH); 149.0 (CH); 142.0 (C); 141.8 (CH); 141.7 (C);
138.3 (CH); 136.3 (CH); 136.0 (CH); 130.21 (C); 130.15
(C); 128.33 (CH); 128.29 (CH); 41.9 (CH2); 38.62 (CH2);
38.60 (CH2); 36.6 (CH2); 36.4 (CH2); 30.0 (CH); 29.5 (CH);
27.3 (2 CH); 24.13 (CH2); 24.07 (CH2); 22.6 (CH3); 22.5
(CH3); 22.4 (2 CH3), 19.8 (CH3); 19.5 (CH3). Note: one of
the CH2 signals, α to the carbonyl, is overlapping with
the DMSO signal. HR-ESI-MS (pos.): 354.118
(C16H25BrN3O
+, [M+H]+; calc. 354.118).
N’-[(5-Bromopyridin-3-yl)methylidene]-3,7-di-
methyloctanehydrazide (31). This compound was
synthesized according to GP-A, starting with 5-bromo-
nicotinaldehyde (68 mg, 0.37 mmol, 1.3 equiv.). The
crude was purified by flash column chromatography
(CH2Cl2/MeOH 98:2) to afford the product as pale
yellow solid (97 mg, 0.27 mmol, 97%). M.p. 81–83 °C.
1H-NMR (400 MHz, (D6)DMSO): 11.60 (s, 1 H); 11.48 (s, 1
H); 8.81 (d, J=1.8, 1 H); 8.79 (d, J=1.8, 1 H); 8.70 (d, J=
2.3, 1 H); 8.69 (d, J=2.3, 1 H); 8.27 (app. t, J=2.0, 1 H);
8.25 (app. t, J=2.0, 1 H); 8.19 (s, 1 H); 7.97 (s, 1 H); 2.68
(dd, J=14.3, 5.8, 1 H); 2.39 (dd, J=14.3, 8.2, 1 H); 2.21
(dd, J=13.9, 6.1, 1 H); 2.09–1.86 (m, 3 H); 1.55–1.43
(m, 2 H); 1.38–1.06 (m, 12 H); 0.92–0.87 (m, 6 H); 0.86–
0.80 (m, 12 H). 13C-NMR (101 MHz, (D6)DMSO): 174.2
(C); 168.4 (C); 150.8 (CH); 150.6 (CH); 146.8 (CH); 146.6
(CH); 141.3 (CH); 137.9 (CH); 135.5 (CH); 135.2 (CH);
132.32 (C); 132.27 (C); 120.53 (C); 120.47 (C); 41.8 (CH2);
39.20 (CH2); 38.60 (CH2); 38.58 (CH2); 36.6 (CH2); 36.4
(CH2); 30.0 (CH); 29.5 (CH); 27.3 (2 CH); 24.15 (CH2);
24.07 (CH2); 22.5 (2 CH3), 22.4 (2 CH3), 19.8 (CH3); 19.5




dimethyloctanehydrazide (32). This compound was
synthesized according to GP-A, starting with 6-methox-
ynicotinaldehyde (49 mg, 0.36 mmol, 1.3 equiv.). The
crude was purified by flash column chromatography
(CH2Cl2/MeOH 98.5 :1.5) to afford the product as white
solid (82 mg, 0.27 mmol, 98%). M.p. 75–76 °C. 1H-NMR
(400 MHz, (D6)DMSO): 11.30 (s, 1 H); 11.22 (s, 1 H);
8.39–8.31 (m, 2 H); 8.17 (s, 1 H); 8.07–7.98 (m, 2 H);
7.95 (s, 1 H); 6.88 (t, J=8.0, 2 H); 3.88 (2s overlap, 6 H);
2.61 (dd, J=14.3, 5.8, 1 H); 2.39 (dd, J=14.3, 8.2, 1 H);
2.17 (dd, J=13.9, 6.1, 1 H); 2.04–1.83 (m, 3 H); 1.59–
1.42 (m, 2 H); 1.36–0.99 (m, 12 H); 0.93–0.87 (m, 6 H);
0.86–0.81 (m, 12 H). 13C-NMR (101 MHz, (D6)DMSO):
173.8 (C); 168.0 (C); 164.4 (C); 164.2 (C); 147.1 (CH);
146.7 (CH); 143.1 (CH); 139.4 (CH) 136.0 (CH); 135.6
(CH); 124.29 (C); 124.28 (C); 111.2 (2 CH); 53.5 (CH3);
53.4 (CH3); 41.9 (CH2); 39.22 (CH2); 38.61 (CH2); 38.59
(CH2); 36.6 (CH2); 36.4 (CH2); 30.0 (CH); 29.5 (CH); 27.3
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(2 CH); 24.13 (CH2); 24.07 (CH2); 22.54 (CH3); 22.51
(CH3); 22.4 (2 CH3), 19.8 (CH3); 19.5 (CH3). HR-ESI-MS
(pos.): 306.218 (C17H28N3O2
+, [M+H]+; calc. 306.218).
N’-[(5-Methoxypyridin-3-yl)methylidene]-3,7-di-
methyloctanehydrazide (33). This compound was
synthesized according to GP-A, starting with 5-methox-
ynicotinaldehyde (46 mg, 0.33 mmol, 1.2 equiv.). The
crude was purified by automated column chromatog-
raphy (CH2Cl2/MeOH 97 :3 to 92 :8) to afford the
product as yellow oil (53 mg, 0.17 mmol, 63%). 1H-
NMR (400 MHz, (D6)DMSO): 11.48 (s, 1 H); 11.38 (s, 1 H);
8.41 (s, 1 H); 8.39 (s, 1 H); 8.32–8.28 (m, 2 H); 8.21 (s, 1
H); 7.99 (s, 1 H); 7.64–7.53 (m, 2 H); 3.87 (2s overlap, 6
H); 2.66 (dd, J=14.3, 5.8, 1 H); 2.40 (dd, J=14.3, 8.2, 1
H); 2.20 (dd, J=13.9, 6.1, 1 H); 2.06–1.83 (m, 3 H);
1.59–1.43 (m, 2 H); 1.37–1.05 (m, 12 H); 0.95–0.87 (m,
6 H); 0.86–0.79 (m, 12 H). 13C-NMR (101 MHz, (D6)
DMSO): 174.1 (C); 168.3 (C); 155.5 (2 C), 142.9 (CH);
141.1 (CH); 140.4 (CH); 139.34 (CH); 139.26 (CH); 138.5
(CH); 131.01 (C); 130.98 (C); 116.6 (CH); 115.8 (CH); 55.6
(CH3); 55.5 (CH3); 41.8 (CH2); 38.61 (2 CH2), 36.7 (CH2);
36.4 (CH2); 30.0 (CH); 29.6 (CH); 27.34 (CH); 27.31 (CH);
24.11 (CH2); 24.07 (CH2); 22.56 (CH3); 22.51 (CH3); 22.4
(2 CH3), 19.8 (CH3); 19.5 (CH3). Note: one of the CH2
signals, α to the carbonyl, is overlapping with the




idene]octanehydrazide (34). This compound was
synthesized according to GP-A, starting with 6-meth-
ylnicotinaldehyde (67 mg, 0.55 mmol, 1.3 equiv.). The
crude was purified by automated column chromatog-
raphy (CH2Cl2/MeOH 97 :3 to 92 :8) to afford the
product as white solid (110 mg, 0.379 mmol, 92%).
M.p. 135–136 °C. 1H-NMR (400 MHz, (D6)DMSO): 11.39
(s, 1 H); 11.29 (s, 1 H); 8.66 (d, J=2.2, 1 H); 8.63 (d, J=
2.2, 1 H); 8.18 (s, 1 H); 7.97 (s, 1 H); 7.96–7.91 (m, 2 H);
7.30 (app. t, J=7.6, 2 H); 2.63 (dd, J=14.3, 6.0, 1 H);
2.49 (2s overlap, 6 H); 2.40 (dd, J=14.3, 8.0, 1 H); 2.18
(dd, J=13.7, 6.0, 1 H); 2.05–1.83 (m, 3 H); 1.56–1.43
(m, 2 H); 1.34–0.98 (m, 12 H); 0.93–0.87 (m, 6 H); 0.85–
0.80 (m, 12 H). 13C-NMR (101 MHz, (D6)DMSO): 174.0
(C); 168.2 (C); 159.4 (C); 159.1 (C); 148.1 (CH); 147.8
(CH); 143.2 (CH); 139.7 (CH); 133.5 (CH); 133.2 (CH);
127.56 (C); 127.55 (C); 123.30 (CH); 123.26 (CH); 41.9
(CH2); 39.22 (CH2); 38.62 (CH2); 38.60 (CH2); 36.6 (CH2);
36.5 (CH2); 30.0 (CH); 29.5 (CH); 27.5 (2 CH); 24.14
(CH2); 24.09 (CH2); 24.0 (2 CH3), 22.57 (CH3); 22.54
(CH3); 22.4 (2 CH3), 19.8 (CH3); 19.5 (CH3). HR-ESI-MS
(pos.): 290.223 (C17H28N3O
+, [M+H]+; calc. 290.223).
2-(2-Chlorophenoxy)-N’-[(pyridin-3-yl)methyl-
idene]acetohydrazide (35). This compound was syn-
thesized using similar conditions to GP-A, starting with
nicotinaldehyde (32 mg, 0.30 mmol, 1.2 equiv.) and 2-
(2-chlorophenoxy)acetohydrazide (50 mg, 0.25 mmol).
The crude was purified by flash column chromatog-
raphy (CH2Cl2/MeOH 96.5:3.5) to afford the product as
white solid (65 mg, 0.22 mmol, 89%). NMR Analysis
showed that the product is a mixture of Esyn and Eanti
conformers (ratio 71 :29). M.p. 152–154 °C. 1H-NMR
(400 MHz, (D6)DMSO): 11.79 (br. s, 2 H); 8.88 (s, 1 H);
8.84 (s, 1 H); 8.64–8.54 (m, 2 H); 8.33 (s, 1 H); 8.17–8.09
(m, 2 H); 8.05 (s, 1 H); 7.52–7.38 (m, 4 H); 7.34–7.21 (m,
2 H); 7.14–6.91 (m, 4 H); 5.30 (s, 2 H); 4.79 (s, 2 H). 13C-
NMR (101 MHz, (D6)DMSO): 168.7 (C); 164.0 (C); 153.6
(C); 153.4 (C); 150.8 (CH); 150.6 (CH); 148.8 (CH); 148.6
(CH); 145.1 (CH); 141.1 (CH); 133.6 (CH); 133.5 (CH);
130.1 (CH); 130.0 (CH); 129.9 (2 C), 128.3 (CH); 128.1
(CH); 124.0 (CH); 123.9 (CH); 122.2 (CH); 121.6 (CH);
121.2 (2 C), 114.1 (CH); 113.8 (CH); 67.0 (CH2); 65.4




ylidene]acetohydrazide (36). This compound was
synthesized using similar conditions to GP-A, starting
with nicotinaldehyde (31 mg, 0.29 mmol, 1.3 equiv.)
and 2-(2,4-dichlorophenoxy)acetohydrazide (51 mg,
0.22 mmol). The crude was purified by flash column
chromatography (CH2Cl2/MeOH 98:2) to afford the
product as white solid (61 mg, 0.19 mmol, 87%). NMR
Analysis showed that the product is a mixture of Esyn
and Eanti conformers (ratio 75:25). M.p. 182–184 °C. 1H-
NMR (400 MHz, (D6)DMSO): 11.80 (br. s, 2 H); 8.88 (s, 1
H); 8.83 (s, 1 H); 8.63–8.57 (m, 2 H); 8.32 (s, 1 H); 8.15–
8.08 (m, 2 H); 8.04 (s, 1 H); 7.66–7.55 (m, 2 H); 7.51–
7.43 (m, 2 H); 7.41–7.29 (m, 2 H); 7.14–7.07 (m, 2 H);
5.32 (s, 2 H); 4.82 (s, 2 H). 13C-NMR (101 MHz, (D6)
DMSO): 168.5 (C); 163.7 (C); 152.8 (C); 152.6 (C); 150.8
(CH); 150.6 (CH); 148.8 (CH); 148.5 (CH); 145.2 (CH);
141.2 (CH); 133.58 (CH); 133.52 (CH); 129.93 (C); 129.85
(C); 129.4 (CH); 129.2 (CH); 128.1 (CH); 127.8 (CH); 125.2
(C); 124.5 (C); 124.0 (CH); 123.8 (CH); 122.5 (C); 122.2
(C); 115.4 (CH); 115.2 (CH); 67.1 (CH2); 65.7 (CH2). HR-




yl)methylidene]acetohydrazide (37). This compound
was synthesized using similar conditions to GP-A,
starting with nicotinaldehyde (33 mg, 0.31 mmol,
1.3 equiv.) and 2-[(1H-benzimidazol-2-yl)sulfanyl]aceto-
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hydrazide (51 mg, 0.23 mmol). The crude was purified
by flash column chromatography (CH2Cl2/MeOH 94 :6)
to afford the product as yellow solid (52 mg,
0.17 mmol, 72%). NMR Analysis showed that the
product is a mixture of Esyn and Eanti conformers (ratio
64:36). M.p. 148–152 °C. 1H-NMR (600 MHz, (D6)DMSO):
12.59 (br. s, 2 H); 12.01 (br. s, 1 H); 11.80 (br. s, 1 H);
8.87 (d, J=1.7, 1 H); 8.83 (d, J=1.7, 1 H); 8.61–8.58 (m,
2 H); 8.27 (s, 1 H); 8.09 (dt, J=8.0, 2.0, 2 H); 8.06 (s, 1
H); 7.58–7.32 (m, 6 H); 7.16–7.08 (m, 4 H); 4.61 (s, 2 H);
4.19 (s, 2 H). 13C-NMR (151 MHz, (D6)DMSO): 169.3 (C);
164.1 (C); 150.7 (CH); 150.5 (CH); 149.7 (C); 149.5 (C);
148.8 (CH); 148.6 (CH); 144.3 (CH); 143.5 (2 C) 140.8
(CH); 135.5 (2 C), 133.5 (CH); 133.4 (CH); 130.02 (C);
129.95 (C); 124.0 (CH); 123.9 (CH); 121.6 (2 CH); 121.1 (2
CH); 117.3 (2 CH); 110.3 (2 CH); 34.2 (CH2); 33.5 (CH2).




ylidene]acetohydrazide (38). This compound was
synthesized using similar conditions to GP-A, starting
with nicotinaldehyde (43 mg, 0.41 mmol, 2.7 equiv.)
and 2-(3,4-dimethoxyphenyl)acetohydrazide (31 mg,
0.15 mmol). The crude was purified by flash column
chromatography (CH2Cl2/MeOH 97:3) to afford the
product as yellow solid (33 mg, 0.11 mmol, 74%). NMR
analysis showed that the product is a mixture of Esyn
and Eanti conformers (ratio 60:40). M.p. 145–148 °C. 1H-
NMR (400 MHz, (D6)DMSO): 11.67 (s, 1 H); 11.46 (s, 1 H);
8.86 (d, J=1.7, 1 H); 8.81 (d, J=1.7, 1 H); 8.58 (dd, J=
4.8, 1.6, 2 H); 8.27 (s, 1 H); 8.13 (app. dt, J=8.0, 2.0, 1
H); 8.07 (app. dt, J=8.0, 2.0, 1 H); 8.02 (s, 1 H); 7.60–
7.40 (m, 2 H); 6.95–6.78 (m, 6 H); 3.91 (s, 2 H); 3.75 (s, 3
H); 3.72 (s, 3 H); 3.70 (s, 3 H); 3.68 (s, 3 H); 3.47 (s, 2 H).
13C-NMR (101 MHz, (D6)DMSO): 172.7 (C); 167.0 (C);
150.6 (CH); 150.3 (CH); 148.7 (CH); 148.6 (C); 148.4 (C);
148.3 (CH); 147.7 (C); 147.5 (C); 143.7 (CH); 139.9 (CH);
133.34 (CH); 133.27 (CH); 130.2 (2 C), 127.9 (C); 127.8
(C); 123.9 (2 CH); 121.3 (CH); 121.1 (CH); 113.3 (CH);
113.0 (CH); 111.9 (CH); 111.8 (CH); 55.6 (CH3); 55.50
(CH3); 55.46 (CH3); 55.3 (CH3); 40.8 (CH2); 38.6 (CH2).
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